Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
News|Articles|January 1, 2002
- Pharmaceutical Technology-01-02-2002
- Volume 26
- Issue 1
Outsourcing Outlook
Author(s)Jim Miller
The author looks ahead to what 2002 may have in store for the contract services industry.
Advertisement
Articles in this issue
over 24 years ago
What Does Pharmacy Automation Mean for Packaging?over 24 years ago
Novel Acrylate Adhesives for Transdermal Drug Deliveryover 24 years ago
Optimal Tablet Press Operation: Machine versus Granulationover 24 years ago
Manufacturers Face Shifting Priorities in the New Yearover 24 years ago
Investigation of Out-of-Specification Resultsover 24 years ago
Reaping the Benefits of E-ProcurementAdvertisement
Related to this article
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Shilpa Pharma Lifesciences Limited will launch a new small-molecule CDMO at CPHI Milan in October.
This article explains the 4 shifts enabling faster, lower-risk, commercially successful biologics technology transfer.
Advertisement
Advertisement